<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-038961
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20060919
<FILING-DATE>20060919
<DATE-OF-FILING-DATE-CHANGE>20060919
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>061097127
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v053088_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>FORM
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
      the month of September 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><strong><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number 000-5112</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></strong></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12
      BGC Centre</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
      WA
      6000</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
      September 19, 2006</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td>
            </td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/
              Aaron Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Aaron
                Finlay</font></div><em><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Company
              Secretary</font></em></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>&#160;</td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: -18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
      INDEX</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Initiation
                of Phase II clinical study of novel ophthalmic
                product</strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.2:</strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Results
                of General Meeting held 19</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>th</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
                September, 2006</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-2-</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v053088_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="50%">
            </td>
            <td width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><IMG SRC="psivida.jpg"></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td width="50%"><strong><font size="2">ASX/MEDIA RELEASE</font></strong></td>
            <td width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><strong><font size="2">&#160;19
                September
                2006</font></strong></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Initiation
      of Phase II clinical study of novel ophthalmic product</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Boston,
      MA. and Perth, Australia - Global bio-nanotech company pSivida Limited (ASX:PSD,
      NASDAQ:PSDV, Xetra:PSI) is pleased to announce the initiation of a Phase II
      clinical trial of Mifepristone (otherwise known as RU486) as an eye drop
      treatment for steroid associated elevated intraocular pressure
      (IOP).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      investigator sponsored trial will involve up to 45 patients in the United
      States. pSivida will be supplying clinical trial material for this study and
      have filed a patent application on this product class. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Elevated
      IOP may occur in patients receiving steroidal treatment for chronic eye
      diseases. The trial will investigate the use of Mifepristone as a means to
      prevent elevation of IOP from intraocular steroid exposure. Mifepristone is
      a
      steroid receptor antagonist (&#8220;steroid blocker&#8221;) already approved by the FDA.
      This study represents a potential new use of an existing drug, made possible
      by
      a new delivery system.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;We
      believe the trial of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mifepristone</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#160;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">as
      a
      treatment for elevated IOP is an important study for the steroidal treatment
      of
      chronic eye disease,&#8221; said Dr Roger Brimblecombe, Executive Chairman and CEO of
      pSivida Limited. &#8220;This program highlights pSivida&#8217;s focus on drug delivery
      strategies to generate clinically significant advances and move products rapidly
      through the regulatory pipeline. There are now two FDA approved products, one
      in
      Phase III clinical trials and two more in Phase II clinical trials all using
      our
      delivery technologies.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is the
      only FDA approved sustained release back of the eye treatment for uveitis,
      a
      leading cause of blindness in the United States. Licensed to Bausch &amp; Lomb,
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      marketed in the United States and covered by Medicare and Medicaid.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      next
      generation product, Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is in
      Phase III clinical trials and is licensed to Alimera Sciences for the treatment
      of diabetic macular edema, the leading cause of blindness for people under
      the
      age of 65 in the United States. Medidur</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      differs
      from Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in that
      it is &#8216;injected&#8217; into the eye through a standard gauge needle in an office
      procedure rather than a surgical procedure.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
      <div>&#160;</div>
    </div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="left" valign="top" width="34%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 943 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="left" valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>European
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accent
                Marketing Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Eva
                Reuter</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +49 (254) 393 0740</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e.reuter@e-reuter-ir.com</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is a global bio-nanotech company committed to the biomedical sector and the
      development of drug delivery products. Retisert&#8482; is FDA approved for the
      treatment of uveitis. Vitrasert&#174; is FDA approved for the treatment of
      AIDS-related CMV Retinitis. Bausch &amp; Lomb own the trademarks Vitrasert&#174; and
      Retisert&#8482;. pSivida has licensed the technologies underlying both of these
      products to Bausch &amp; Lomb. The technology underlying Medidur&#8482;, a treatment
      for diabetic macular edema, is licensed to Alimera Sciences and is in Phase
      III
      clinical trials.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns the rights to develop and commercialise a modified form of silicon
      (porosified or nano-structured silicon) known as BioSilicon&#8482;, which has
      applications in drug delivery, wound healing, orthopaedics, and tissue
      engineering. pSivida&#8217;s subsidiary, AION Diagnostics Limited is developing
      diagnostic products and the subsidiary pSiNutria is developing food technology
      products both using BioSilicon&#8482;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      intellectual property portfolio consists of 70 patent families, 74 granted
      patents and over 290 patent applications.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      pSivida
      conducts its operations from offices and facilities near Boston in the United
      States, Malvern in the United Kingdom, Perth in Australia and Singapore.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      and on
      the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
      Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company's largest shareholder and a strategic partner is QinetiQ, a leading
      international defence, security and Technology Company, formed in 2001 from
      the
      UK Government's Defence Evaluation &amp; Research Agency (DERA). QinetiQ (QQ.)
      was instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      pSivida&#8217;s strong relationship with QinetiQ includes access to its cutting edge
      research and development facilities.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties. The statements reference potential products, applications and
      regulatory approvals. Although we believe that the expectations reflected in
      such forward-looking statements are reasonable at this time, we can give no
      assurance that such expectations will prove to be correct. Given these
      uncertainties, readers are cautioned not to place undue reliance on such
      forward-looking statements. Actual results could differ materially from those
      anticipated in these forward-looking statements due to many important factors
      including: our inability to raise additional funds at favourable terms or any
      terms; our inability to repay the amended notes; issues relating to share
      registration in the U.S. that may delay our registration; our inability to
      develop proposed products, including without limitation, in the drug delivery,
      wound healing, orthopaedics, and tissue engineering, diagnostics and food
      technology fields; failure of our evaluation agreements to result in license
      agreements; failure to develop applications for BioSilicon&#8482; due to regulatory,
      scientific or other issues; failure to complete negotiations for new centers
      for
      the BrachySil&#8482; phase&#160;IIb clinical trial for inoperable primary liver
      cancer; failure of our discussions with the FDA for BrachySil&#8482; to continue or to
      lead to FDA approval; failure of the BrachySil&#8482; phase&#160;IIb clinical trial
      for inoperable primary liver cancer to determine the optimal dose, provide
      key
      safety data or support future pivotal efficacy trials or product registration
      or
      approval; failure of the BrachySil&#8482; primary liver programme that is in
      phase&#160;IIb clinical trials to&#160;provide a valuable platform for the
      development and commercialisation of BrachySil&#8482; for pancreatic cancer and other
      indications; failure to commence phase&#160;IIa BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      trials
      for the treatment of pancreatic cancer; failure of the findings&#160;of the
      pancreatic cancer phase&#160;IIa trial to provide a platform for further
      multicentre efficacy and safety trials; failure of there to be
      optimisation&#160;and standardisation between our two&#160; pancreatic
      cancer&#160;study&#160;centres; failure of the results of the Retisert&#8482; for DME
      trial to be a good indicator of the results of pSivida&#8217;s ongoing phase&#160;III
      Medidur&#8482; for DME trial; failure of the Medidur&#8482; trials in DME to show a very
      similar improvement in visual acuity and diabetic retinopathy severity score
      as
      Retisert&#8482; for DME; failure of Medidur&#8482; to release fluocinolone acetonide at the
      same rate as Retisert&#8482;; our inability to recruit patients for the phase&#160;III
      Medidur&#8482; for DME trial. Other reasons are contained in cautionary statements in
      the Annual Report on Form 20-F filed with the U.S. Securities and Exchange
      Commission, including, without limitation, under Item 3.D, "Risk Factors"
      therein. We do not undertake to update any oral or written forward-looking
      statements that may be made by or on behalf of pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>psivida.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 psivida.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_[1(F4&AO=&]S:&]P(#,N,``X0DE-!"4`
M`````!``````````````````````.$))30/M```````0`[#,S0`!``$#L,S-
M``$``3A"24T$)@``````#@`````````````_@```.$))300-```````$````
M>#A"24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))300*
M```````!```X0DE-)Q````````H``0`````````".$))30/U``````!(`"]F
M9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&
M```````!`#4````!`"T````&```````!.$))30/X``````!P``#_________
M____________________`^@`````_____________________________P/H
M`````/____________________________\#Z`````#_________________
M____________`^@``#A"24T$`````````@`!.$))300"```````$`````#A"
M24T$"```````$`````$```)````"0``````X0DE-!!X```````0`````.$))
M300:``````-)````!@`````````````"Q0``"3H````*`%4`;@!T`&D`=`!L
M`&4`9``M`#$````!``````````````````````````$`````````````"3H`
M``+%``````````````````````$`````````````````````````$`````$`
M``````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M``+%`````%)G:'1L;VYG```).@````9S;&EC97-6;$QS`````4]B:F,````!
M```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$
M;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T
M;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R``
M```&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``
M````````3&5F=&QO;F<``````````$)T;VUL;VYG```"Q0````!29VAT;&]N
M9P``"3H````#=7)L5$585`````$```````!N=6QL5$585`````$```````!-
M<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E;&Q497AT
M27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG
M;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L
M:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O
M;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET
M;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T
M=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-
M!"@```````P````!/_`````````X0DE-!!0```````0````".$))300,````
M``Q2`````0```*`````P```!X```6@````PV`!@``?_8_^``$$I&248``0(!
M`$@`2```_^T`#$%D;V)E7T--``'_[@`.061O8F4`9(`````!_]L`A``,"`@(
M"0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1
M#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``P`*`#
M`2(``A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$``````````P`!`@0%!@<(
M"0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(
M!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/P
MX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U
M`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086
MHK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5))5,]^54SUJ
M;&L:SZ3'-;!)/MFQ]E.Q,R3]N!GPF0CJ1'YJ_P`)(%MM)4L7,MS,,V4!C,AI
MVN#I+`1&[Z/NVN9]%4'=9Z@W(..64[P_TYAT3.W]Y5LOQ#!CCCF>(PR@<$HQ
ML&_T?[R1`F_!TNH=2P.F8QRL^]N/2#&YYY<?HUUL'OMM=^957^D68W)^L75S
MNQ6?L7!/T;LA@?F/'MUKPW?H,)OT_P"E_:+O^ZE2)=@X>':[K6;2R[J0&RJS
M=8\-!TV8S,AUC,7=_A?L[*T6O+Z@:'7MV9%K_P!'3C,#0WU#'N?D,LOVT5_X
M5W\Y_P`$^STJK)AS,/<CB$9')(<9%?S<?]8L,31)-1_J]6CTW[?C?6B[IS<^
M_/PV8@NROM'IN-=UEFW'8Q^/51Z?JTUW/]':NB5'I/2V].H>'6'(RLAYNS,I
MPAUMK@`Y^WW>G4QK6U8]/^`HKKJ5Y3E$10_%222H]0ZK5A.%>TV6D3MF`!_*
M=JHLV;'A@<F60A`=2O`)-!O)++Q^N-?<*<FHT%Q`!)F"?H[PYK'-W*WGW9--
M`?C5^K9N`VP3H>3[84<.<PSQSRXY&<<?SB(EQC_J<O6HQ(-'JV4D+&?;9CUO
MN;LL<T%[8B#X:HJGC(2B)#](7KXH4DLSZQ9O5,'IC\CI6/\`:\L/8&TEKGRU
MS@VQVRIS'^UB+T3*S\OI6/D]1I^S9EC2;J=I;M,D1LL+GM]J=6EK>(<7#UJV
M\DJG5<[]G=-RL_9ZOV6I]OISMW;!NV[X?M_S53^K/7CU_ISLTX_V;;:ZKT]_
MJ?1#3NW;*_WTJ-6HSB)"-^HBZ==)))!<_P#_T/54',G[,\MD$`&02.#/+7T_
M^?$98G7NK9;+ZNB](`=U;,:7>HX;F8U`.RS.O9^=M^ACU._GKTV<..,H_O`Q
M^U!D(ZEJBSJVS*QND>G]KR+FM]>PAS:*W"QUF;Z>^S[2]D,973ZG\];7ZWZ+
MU%!X(ZGM)W%MS07'DD.:'//]?Z2UK>D/>YEK<JQMS&@;X$?RMH;MV-<[_![]
MBQGLL&<:S838+=OJQKNW1ZFU<[ST,N'%@PSAICS$PR`Q_6\4N.J^:/S,T*),
MKW&W9U^NN&S'JG5UH/AH!'BS]_\`?5S!G[.'$D[B2"23I/B;+_\`SXJM/27"
M[UKLJRUXT)'MTYV?GNV_U%H@`"`(`X"U^7Q93GR<QEC[?&!&,+C.7#'O*"PD
M4`-5UPG4.L_61_UWR.C=.RVULL`90RYK377./7D67>UGJV6,_2/JK<_T_5_G
M/T2[M>?2&_XUR7$`;HU\3A`!7X=?(M?F"0,=$B\D0:[%+T7JW7^F_7$]!ZIF
MG.JN+AO<`!)K^TTVU>T.K^CZ3Z?YM;_5ZKL?.;G!NZOVND\!S=-K_P!W<N:R
MR+/\:=(9[BQS`Z.Q&,][O^BY=E?U6JK,^R6UEK#`=8XC;#AH8_<W>Q4OBD,4
M\,!DR>S<H''.OES?H6NY0R_6#YA&<HZ_NL*[>F=5>SU6?IV`Q6XD3W,;?;:U
M%ZQ?=1B!]+RQV]HD0=#_`%I67UBG&QKV/Q2&/(+RUIT:1!8]O[NY7^N$GI[2
MX02]LCS5'W\GL\["8C'F,,1QY\/I]VX^B7%^_%L4+CV/0N9]9\SJM'U5;U#!
MR749%)JLM>T-)<QQ]*QL/8]G^%]7_K:H=2^M.8SZAX?4JKC7GY)KH-X#9%E9
M=]JLVN;Z?Z1N-=^9_A%TC<-F=T$X5FC,G'-1/AO:6;O[,KR?"&3U%O3_`*NV
M!S8S7[_+U?2JN&W_`(#TLJS_`*ZMCE?5@QDZGAB23_=:7,SE"9HG]8."/]_B
M>YZGU'K6#]0\?.=E/_:-@ILLOVLW?IGM?Z>PL]/V5V>C_-JW@]=RZ/J*WK60
M_P"T9;,=S]SP(=9N<RK>VOT_;OV?03?XPP!]5K@!`%M(`'_&,6;M+O\`%7`$
MQCS\A;N<I``0/&2I2E')(`GTXK_P@YF+9];L[ZL]1ZM=GMR,.VNZN[&O:)<Q
MK7,OOQW5!GH65^[T:OYJS_"+9^H%[\;ZIY6174Z]]-U[VTLU<\M8QS:F?R[/
MH*MT:ZH_XL\X;P#77E,=)`ASB]S&?UG^K7M_KJ7U-ZFSI7U*S>HO8;!CW6N%
M8,;G14VMF[7;O>YON1.QTZL>/2>,F1_FS(DZM-W_`(X6;A9?6+\MW3FX@>\8
MA;Z1+6-]9_I5^F_<S;[*WY#[/572_4GKF7UKHQOS(=D46NH?8T!N^&UVMLV-
M]K';+O?M7+,QNH_6'H>=]8.N=2<,:IEIQL&IPKI]2N?2]5G_`!OZ.JM_ZS9^
MC_3K8_Q7_P#(65//VQW_`)ZQDI?*=M"G#(^[$7+AE$R]1^;^M7Z+_]'TOJG4
M*NF=-R>H7":\6IUI:.3M$A@_E/=[%0^K/2[\/$LS<\[NK=2<,C.>?S71^BQ6
M?NTX=?Z&MO\`74OK$>JMHJ?@8C.I5$N9FX#W-9ZE3VN;[7V_H_8_;['?38J@
MS?KIGC9C]/Q^D,/TK\JW[0^#WIQL7:SU&_\`#7(]&,D<6H)K:A^UVL[/PNGX
MSLK.O9CT,YLL(:)[-;^\]WYC&^]<PY]N3G&YP?AXUEQ+0\;,E[2X;;/3>/\`
M)U'_`!_Z_9_H</\`GEK=/^K.-CY+>H=0NLZKU-OT<K)@BN>?L>,W]!AM_P"*
M9ZO_``JTOL.$22<>LDZDEC223W.BJ<YRQS"'"(&4#Q1.2Y1B?]G^E_ALD2=;
MT!Z#?_&9TMJ;6&TP6#@@SKWEWYSOWD10JJJI;LJ8VMLSM:`!/P:IJR+H<5<7
M6ME>2EYMU#`Q>I?XR[L',9ZF/?`>T$M/MPVV,<US8<US'L:]>DJM^S>G?;/M
M_P!EI^V?]R?3;ZOT?2_GMOJ?S?Z/Z7T$Z)J_*F/+CXQ$?NR$CX\/1Q^A?4GI
M71<UV=59=DY$.;6^\M.P.^FYOILK_2/_`#K'+7S.GXV8`;00]NC7MT='@K22
M9EA#+$QR1$XG<2U7PB("HCA\G/QNB8=%@L)=86F6AT0#^]M:&JSF8E>75Z5A
M<ULATM@&1\0Y'244.5P0QRQQQQC"?S1'Z7]Y=Q&[M'12VBEE+"2VL!H)Y@+&
MQ?J=TK%ZZ[KE;[CDNLLM]-SFFH.N#FV%K16+/\(__"K=24\1P@1CH`.&O!;*
M(D02+HV/-H=:Z/C=:P'8&4^RNI[FO+JB`Z6$/;J]MC>W[J6%T;#Q.CMZ,-UV
M(*W4N%I!<YC]V]KW5BO]_P#-5])*SLKAC?%6M5]'D\;_`!;=!I=87V9%[7M<
MUC+'-(82"QMS0VMOJ75;OT+[O4V+4Z?]5NF8'1[^C`V9&)DEYM%Q!=[P&NVN
MJ95MV[?8MA)$R)ZK8XL<=H@?VO)8_P#BTZ#4YQMNR<AI!VLL>T-:2-K;=M5=
M>^VO\S?_`)BVN@=`Q.@XEF)B66VUVV&YQN+2[<6LKT]-E7MVU-6FDD9$[E4<
M4(FXQ`?_V3A"24T$(0``````4P````$!````#P!!`&0`;P!B`&4`(`!0`&@`
M;P!T`&\`<P!H`&\`<````!(`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O
M`'``(`!#`%,````!`#A"24T$!@``````!P`(`````0$`_^$-:$5X:68``$E)
M*@`(````!P`2`0,``0````$````:`04``0```&(````;`04``0```&H````H
M`0,``0````(````Q`0(`&P```'(````R`0(`%````(X```!IAP0``0```*(`
M``#,````L`,```$```"P`P```0```$%D;V)E(%!H;W1O<VAO<"!#4R!7:6YD
M;W=S`"`R,#`V.C`Y.C$Y(#`W.C(W.C,W``,``:`#``$````!`/__`J`$``$`
M```Z"0```Z`$``$```#%`@````````8``P$#``$````&````&@$%``$````:
M`0``&P$%``$````B`0``*`$#``$````"`````0($``$````J`0```@($``$`
M```V#````````$@````!````2`````$```#_V/_@`!!*1DE&``$"`0!(`$@`
M`/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,`"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]52253/?E5,]:FQK&L^D
MQS6P23[9L?93L3,D_;@9\)D(ZD1^:O\`"2!;;25+%S+<S#-E`8S(:=K@Z2P$
M1N^C[MKF?15!W6>H-R#CEE.\/].8=$SM_>5;+\0P8XXYGB,,H'!*,;!O]'^\
MD0)OP=+J'4L#IF,<K/O;CT@QN>>7'Z-=;![[;7?F55_I%F-R?K%U<[L5G[%P
M3]&[(8'YCQ[=:\-WZ#";]/\`I?VB[_NI4B78.'AVNZUFTLNZD!LJLW6/#0=-
MF,S(=8S%W?X7[.RM%KR^H&AU[=F1:_\`1TXS`T-]0Q[GY#++]M%?^%=_.?\`
M!/L]*JR8<S#W(XA&1R2'&17\W'_6+#$T234?ZO5H]-^WXWUHNZ<W/OS\-F(+
MLK[1Z;C7=99MQV,?CU4>GZM-=S_1VKHE1Z3TMO3J'AUAR,K(>;LS*<(=;:X`
M.?M]WIU,:UM6/3_@**ZZE>4Y1$4/Q4DDJ/4.JU83A7M-EI$[9@`?RG:J+-FQ
MX8')ED(0'4KP"30;R2R\?KC7W"G)J-!<0`29@GZ.\.:QS=RMY]V330'XU?JV
M;@-L$Z'D^V%'#G,,\<\N.1G''\XB)<8_ZG+UJ,2#1ZME)"QGVV8];[F[+'-!
M>V(@^&J*IXR$HB0_2%Z^*%)+,^L6;U3!Z8_(Z5C_`&O+#V!M):Y\M<X-L=LJ
M<Q_M8B]$RL_+Z5CY/4:?LV98TFZG:6[3)$;+"Y[?:G5I:WB'%P]:MO)*IU7.
M_9W3<K/V>K]EJ?;Z<[=VP;MN^'[?\U4_JSUX]?Z<[-./]FVVNJ]/?ZGT0T[M
MVRO]]*C5J,XB0C?J(NG722207/\`_]#U5!S)^S/+9!`!D$C@SRU]/_GQ&6)U
M[JV6R^KHO2`'=6S&EWJ.&YF-0#LLSKV?G;?H8]3OYZ]-G#CC*/[P,?M09".I
M:HLZMLRL;I'I_:\BYK?7L(<VBMPL=9F^GOL^TO9#&5T^I_/6U^M^B]10>".I
M[2=Q;<T%QY)#FASS_7^DM:WI#WN9:W*L;<QH&^!'\K:&[=C7._P>_8L9[+!G
M&LV$V"W;ZL:[MT>IM7.\]#+AQ8,,X:8\Q,,@,?UO%+CJOFC\S-"B3*]QMV=?
MKKALQZIU=:#X:`1XL_?_`'U<P9^SAQ).XD@DDZ3XFR__`,^*K3TEPN]:[*LM
M>-"1[=.=GY[MO]1:(``@"`.`M?E\64Y\G,98^WQ@1C"XSEPQ[R@L)%`#5=<)
MU#K/UD?]=\CHW3LMM;+`&4,N:TUUSCUY%EWM9ZMEC/TCZJW/]/U?YS]$N[7G
MTAO^-<EQ`&Z-?$X0`5^'7R+7Y@D#'1(O)$&NQ2]%ZMU_IOUQ/0>J9ISJKBX;
MW``2:_M--M7M#J_H^D^G^;6_U>J['SFYP;NK]KI/`<W3:_\`=W+FLLBS_&G2
M&>XL<P.CL1C/>[_HN797]5JJS/LEM9:PP'6.(VPX:&/W-WL5+XI#%/#`9,GL
MW*!QSKY<WZ%KN4,OU@^81G*.O[K"NWIG57L]5GZ=@,5N)$]S&WVVM1>L7W48
M@?2\L=O:)$'0_P!:5E]8IQL:]C\4ACR"\M:=&D06/;^[N5_KA)Z>TN$$O;(\
MU1]_)[/.PF(QYC#$<>?#Z?=N/HEQ?OQ;%"X]CT+F?6?,ZK1]56]0P<EU&12:
MK+7M#27,<?2L;#V/9_A?5_ZVJ'4OK3F,^H>'U*JXUY^2:Z#>`V1967?:K-KF
M^G^D;C7?F?X1=(W#9G=!.%9HS)QS43X;VEF[^S*\GPAD]1;T_P"KM@<V,U^_
MR]7TJKAM_P"`]+*L_P"NK8Y7U8,9.IX8DD_W6ES,Y0F:)_6#@C_?XGN>I]1Z
MU@_4/'SG93_VC8*;++]K-WZ9[7^GL+/3]E=GH_S:MX/7<NCZBMZUD/\`M&6S
M'<_<\"'6;G,JWMK]/V[]GT$W^,,`?5:X`0!;2`!_QC%F[2[_`!5P!,8\_(6[
MG*0`$#QDJ4I1R2`)].*_\(.9BV?6[.^K/4>K79[<C#MKNKNQKVB7,:US+[\=
MU09Z%E?N]&K^:L_PBV?J!>_&^J>5D5U.O?3=>]M+-7/+6,<VIG\NSZ"K=&NJ
M/^+/.&\`UUY3'20(<XO<QG]9_JU[?ZZE]3>ILZ5]2LWJ+V&P8]UKA6#&YT5-
MK9NUV[WN;[D3L=.K'CTGC)D?YLR).K3=_P".%FX67UB_+=TYN('O&(6^D2UC
M?6?Z5?IOW,V^RM^0^SU5TOU)ZYE]:Z,;\R'9%%KJ'V-`;OAM=K;-C?:QVR[W
M[5RS,;J/UAZ'G?6#KG4G#&J9:<;!J<*Z?4KGTO59_P`;^CJK?^LV?H_TZV/\
M5_\`R%E3S]L=_P">L9*7RG;0IPR/NQ%RX91,O4?F_K5^B__1]+ZIU"KIG3<G
MJ%PFO%J=:6CD[1(8/Y3W>Q4/JSTN_#Q+,W/.[JW4G#(SGG\UT?HL5G[M.'7^
MAK;_`%U+ZQ'JK:*GX&(SJ51+F9N`]S6>I4]KF^U]OZ/V/V^QWTV*H,WZZ9XV
M8_3\?I##]*_*M^T/@]Z<;%VL]1O_``UR/1C)'%J":VH?M=K.S\+I^,[*SKV8
M]#.;+"&B>S6_O/=^8QOO7,.?;DYQN<'X>-9<2T/&S)>TN&VSTWC_`"=1_P`?
M^OV?Z'#_`)Y:W3_JSC8^2WJ'4+K.J]3;]'*R8(KGG['C-_08;?\`BF>K_P`*
MM+[#A$DG'K).I)8TDD]SHJG.<L<PAPB!E`\43DN48G_9_I?X;)$G6]`>@W_Q
MF=+:FUAM,%@X(,Z]Y=^<[]Y$4*JJJ6[*F-K;,[6@`3\&J:LBZ'%7%UK97DI>
M;=0P,7J7^,N[!S&>ICWP'M!+3[<-MC'-<V'-<Q[&O7I*K?LWIWVS[?\`9:?M
MG_<GTV^K]'TOY[;ZG\W^C^E]!.B:ORICRX^,1'[LA(^/#T<?H7U)Z5T7-=G5
M679.1#FUOO+3L#OIN;Z;*_TC_P`ZQRU\SI^-F`&T$/;HU[='1X*TDF980RQ,
M<D1.)W$M5\(B`J(X?)S\;HF'18+"76%IEH=$`_O;6AJLYF)7EU>E87-;(=+8
M!D?$.1TE%#E<$,<L<<<8PG\T1^E_>7<1N[1T4MHI92PDMK`:">8"QL7ZG=*Q
M>NNZY6^XY+K++?3<YIJ#K@YMA:T5BS_"/_PJW4E/$<($8Z`#AKP6RB)$$BZ-
MCS:'6NCXW6L!V!E/LKJ>YKRZH@.EA#VZO;8WM^ZEA=&P\3H[>C#==B"MU+A:
M07.8_=O:]U8K_?\`S5?22L[*X8WQ5K5?1Y/&_P`6W0:76%]F1>U[7-8RQS2&
M$@L;<T-K;ZEU6[]"^[U-BU.G_5;IF!T>_HP-F1B9)>;1<07>\!KMKJF5;=NW
MV+821,B>JV.+'':(']KR6/\`XM.@U.<;;LG(:0=K+'M#6DC:VW;577OMK_,W
M_P"8MKH'0,3H.)9B8EEMM=MAN<;BTNW%K*]/395[=M35II)&1.Y5'%")N,0'
M_]G_X@Q824-#7U!23T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'
MS@`"``D`!@`Q``!A8W-P35-&5`````!)14,@<U)'0@``````````````````
M]M8``0````#3+4A0("``````````````````````````````````````````
M`````````````````````!%C<')T```!4````#-D97-C```!A````&QW='!T
M```!\````!1B:W!T```"!````!1R6%E:```"&````!1G6%E:```"+````!1B
M6%E:```"0````!1D;6YD```"5````'!D;61D```"Q````(AV=65D```#3```
M`(9V:65W```#U````"1L=6UI```#^````!1M96%S```$#````"1T96-H```$
M,`````QR5%)#```$/```"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT
M`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N
M>0``9&5S8P`````````2<U)'0B!)14,V,3DV-BTR+C$``````````````!)S
M4D="($E%0S8Q.38V+3(N,0``````````````````````````````````````
M````````````````````````````6%E:(````````/-1``$````!%LQ865H@
M`````````````````````%A96B````````!OH@``./4```.06%E:(```````
M`&*9``"WA0``&-I865H@````````)*````^$``"VSV1E<V,`````````%DE%
M0R!H='1P.B\O=W=W+FEE8RYC:```````````````%DE%0R!H='1P.B\O=W=W
M+FEE8RYC:```````````````````````````````````````````````````
M``````````!D97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92`M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````````
M````````````9&5S8P`````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0``````````````+%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````````````
M`````````````'9I97<``````!.D_@`47RX`$,\4``/MS``$$PL``UR>````
M`5A96B```````$P)5@!0````5Q_G;65A<P`````````!````````````````
M`````````H\````"<VEG(`````!#4E0@8W5R=@````````0`````!0`*``\`
M%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!
M`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``
M]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#
M`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"
M00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A
M`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$
M.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W
M!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&
M]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6
M"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*
M@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.
M#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.
M[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M
M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4
M211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!
M%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:
MGAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6
M'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA
M^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W
M)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J
M:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N
M+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S
M\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%
M.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^
MH#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'
M1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*
M?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[
M40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17
MDE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL
M7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)E
MYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@
M;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AU
MA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA
M?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&
M<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\V
MCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8
MN)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(F
MHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL
M7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9Y
MMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!
M9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPU
MS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7
MX-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-C
MX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#O
MS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'
M_)C]*?VZ_DO^W/]M____VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2$P\4
M'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#`0D)
M"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!)`/$#`2(``A$!`Q$!_\0`'P```04!
M`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]
M`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE
M)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0``
M``````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q
M!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V
M-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MXN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HI-RDXW#/I
MFEH`****`"H;N[MK"UDNKN>."",9>21@JJ/J:P/$7BQM(E6RL-+O=2U*3B.*
M*)A&#_M2$;0*Q[7P3?Z_=1ZEXVO1=,IW1Z9`2MM%]1_$?\\CBG;N9RJ._+%7
M9*?'%_KLSP>$=(>]C4[6U"Z)BMP?;NWX5D^(M7\<^$;!-;O[_3;NV$BK+9Q0
M%>O8,>3Z5Z5!'##"D-ND<<4:A42,`*H'0`#H*X76U;QGXSMM%@&[2M'E6XU"
M4?=:;'RQ`]R!R?3\*J+7R,ZD9*.^IW4$GG01R[2N]0V#U&14E'2BH.@****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#G-8TF"
M)FN(PWFS.26:X$84^V>M2^'=3EN/,L[E]\L0RKYR67H<GOCCGWJ[K*EK5-I<
M'?\`PVXE/3T/\ZY_3&^S^),NQ5<-N9XQ'QMSR.U?.5_]EQ\'25E)I/:SO^-[
MFR]Z#N7M9TZ:V@GO8[^X^]GR]Q`&3T&/K6#%<7<L\<0NYAO=4SYAXR<>M.;Q
M>_B6[U.#3K8MHEI#M-ZPQYL_F)@+_L[=W_UN,Q6?_'_;?]=D_P#0A7F9U35'
M'0A"Z4DF]7U;'1FIP;1VVGZ<]B7+7<T^X#B0Y`^E<Y>ZA+JE^Z[P+2,G$?G"
M/</7)KK+IS':3.#@JC$'\*XK3$8P.5,@Y`^6T6;MZGI7IYK^Z=+"T[J+NVO3
MU?<4-;R9KS6L]A9?9=&4I?WBC]Y(V]+<=W/KC/`[G':M+1-%M-`TN.PLPQ12
M7>21MSRNQRSL>[$\_H,``5?10%'K@#IBG5[]&G&E34(*R1@U>7,PHJKJ5P]G
MI=W<QA2\,+R*&Z$@$C->2:1\9-1D\\ZC86TC>2/LT-JCAI9B1@$DG"XR3QGZ
MULHM[&52O"FTI/<]EHKP]_BUXJL=3`U#3K1(P<O:M`\;[?9BQ_/%>RZ;J$.K
M:5;:A:MF&XC$B9ZC(Z'W%$HN.X4L1"JVH[HP]5\1RI/)!9;5"$JTK#)SWP.E
M4%UW5H75I)BP/19(E`/Y`&J-LZ6]]&]PA98Y/WBXR>#S7:W4%MK.GE$D1E;E
M)!SM-?%X:>,S!U*D:SC);1V_KM^9W2Y865@TK5(]3MRX79(G#IGI_P#6JMX@
MCO)+>$68F+!SN\HX.,5+IFBQ:9(TB32.[+M.<`?E3=<U*;38(7A6-B[[3O!]
M/:O<J.I]0?UQ\KMJUZF:MS^Z+H*726#"\$HD\PX\PY..*U*S='OYM1L'FD$:
MR!RHV@XKS?3?B?K;>,H-%U.UL(X3=FVE:-'#`Y*@C+$=<5VX",7AH>S;:MN]
MS"M5C3DE+J>M45S/COQ+-X5\-M?VT<4ER\R11+*"5)/)S@@]`:H?#SQ5JWBR
MTO;O48+6**&01Q>0C#<<9.22?:NKE=KDNK'VGL^IQ>KZ=XV?QU<2VR:Q_9QU
M`,I25A'Y>\=!GIBO::\EU3XH:W9>,I]'CM;`V\=Z+<,R/NVE@,_>QGGTKU2\
MNHK&RGNYVVPPH9'/H`,FJG?2YEAW"\^5MZZW)J\L^)'CC7O#7B*&STR>!('M
M5E(D@#G<68=<^PK#?XN^)K[5=NEV%H868^5;&!Y)&7W(8<X]!7.>.?$?_"3Z
MO;W;V<MG<16PAG@D_A<,QX[XP1U`JX4W?WCGQ&,BZ;]F]3W[PW>SZEX:TZ]N
MF5IYX%>0JNT$D>G:M2L+P:0/!>CDG`%HG\J\^\2?&"Z349+3P]:P-$C[!<3J
M7\QLX^501QZ<\UFHMNR.J5>%.FI3>YZ]17A]G\8?$-I>*-4L;2>$'YXTB:&0
M#V)8C\Q7LVG:A;ZKIMO?VC[[>XC$D;=.#Z^]$H..Y5+$4ZM^5[%JBBBI-@HH
MHH`K:A")[*1"%.!N&]RHR/4CD5QUW&MO=B1Q;LOW)88YBYP1@YW<\@XK/\0Z
MC=>/->D\)Z-(T>EVY_XFEZO0\_ZM?7ICW.>PY[A="TY;*"U\C<D$:QHS,2VT
M#`R>IKS,RR^6(2G3:4UM\MM0I5DVU;0QY9-'MO"WV#2Q%#$BJ$@`P1R.W<UB
M6K!;VW9B`HE0DGL-PK>U?0K.ST^6YA,@9,8!;(Y(%8$$8EN88FSM>15./0D"
MOE<VEB7C*?MTN:RVV>K.JFHJ+4=CI]:UNV^Q26UM*)995V$KR%!Z\_2J6CZ?
MYC*O^C2@-ND9)WW*/3`XK4C\-:<A^97?_>>M2&"*WC$<,:H@[*,5]##`8FOB
M%7Q=K+9+7\_S,N9)6B24445[AD4-<_Y`&H_]>LG_`*":\,^$2JWCJVW*#BTE
M(R,X/R\U[GKG_(`U'_KUD_\`037AOPA_Y'JW_P"O.7_V6M8?"SAQ'^\4_F;O
MQLA1=1T>8*`[12JS=R`5(_F?SKM?A@[/\/\`3=QSMWJ/IO-<7\;9%-_HT8(W
MB*5B.X!*X_D?RKL/AH)8OAS8LL>Y]LC(I.-WS'%*;M33%2_WR?H:^K^'UO':
MXMF6.<_>4_=?_`US@:^TBZP-\$O<'HW]#6Q:>)Y9;Z);A(HH&.&QG(],FM+Q
M`MNVD2F;;D<QGON]J^0Q&'PF,A/&827+*.KZ>?ROW/63E&T9#]'U9=3@;<H2
M=/OJ.GU'M5#Q9_QZVW_70_RK/\,;O[6..GEG=6AXL_X];;_KH?Y5H\7/%9/.
M=3?;UU0N51J61-X6_P"04W_75OZ5XS\3;%]&\?2W<(VB<)=QX_O#K^JY_&O9
MO"W_`""F_P"NK?TKAOC5IF_3=,U51S%,;>3_`'7&0?P*X_X%7MY,[82EZ'!F
M,.:FVNFIE?%O7%U*TT"*(D1S0?;2I_V@`N??[WYUWWPXTW^S/`VG*5*O.IN&
MS_M\C],5X,ANO$FIZ5IQ.'816,9Z[5+8W'Z`D_A7U%%&D,211J%1%"JHZ`#H
M*]*I[L5$Y\(_:U95OD?.6O\`_)4+O_L*K_Z&M>U?$!V3P%K+*2#]GQD>Y`KQ
M77_^2H7?_857_P!#6O:OB"I;P#K(49/D9_443^R3AMJOJSS;X+P1OXDU"5E!
M>.T`0D=,MS_*J_QD15\80%5`+62EB!U.YNM6O@M(@\1:E&2`SVBE1Z@/S_,5
M6^,I_P"*PM^>EBO_`*&]7_R],'_N*]3U3PK"+CP'ID#,RB2R5"R'!&5QD>]<
M[;^$/!G@&]AUBYOY(WA4B(74H?DC&0H&2?IZFM73-570_A7;:HR;_LVG"14S
MC<P7@?B<"O*?"FC7'Q$\732ZQ>NZQIYT[`_,PS@(G]T9_3W.:S2W?0[*E1+D
MBHWD]A?B-XJTGQ3J5K-ID,RF!&22:6,)Y@)&,#.<#GKBO5OAD<_#O2<_W9/_
M`$:]>=_%;2=+T1]'LM,MH;=520LB?>/(P6[GOUKT3X9?\D[TG_=D_P#1KTY6
MY%8SPZDL5+FWM_D=;1116)Z05Q7Q"\175A;6VAZ1\VL:HWE1!3S&G0O[?7ZG
MM79R2+%$\CD*B`LQ/8"N+TW1;J7XJ:OK&H0OY<5O%'8.1\A0CG!]0=V1U^;T
M(JH]V95;M<JZFWX5\-VOA;0H=/M\-)]^>;',LAZD_P`AZ`"MNBN:\1>.M$\-
MMY$]P;B^;A+.V&^0GL"!]W\>O;-+5LJ\:<==$:7B`9T2XQ_L_P#H0K@K2\>[
MU)(-,6.>2&5?-N')\B!LC"LP^\Y./D7GUQ5R>#Q)XHA$VMP7&GZ4YRFEVF?.
MF';S7'W1[#FK,=E?0_9D@TQX;>V8&&WCB*H@!S_^L]:^:S>E16)C6DG)I)62
M=M[W;7Y(UI2E*-EHCL;*S:V3,L[W$[??E?C/T`X`]A5JJ.GWT]VSB:REM]H&
M"_\`%5ZOH:=6-6//';[OS)M;0****L"AKG_(`U'_`*]9/_037SIX(T677]>C
MLK>]DLKE;=YH9TZJZ[<9[XY/2OHW6(WET2_CC1G=[>1551DDE3@"O'?A=X=U
MO3/&4%Q?Z3>6T`M)%,DT1503MP,_A6L':+.'$T^>M336FI7N?AMXVU?5P=2>
M.3)"->RW(<!1Z#[WX8%>U:1ID.C:1:Z=;Y,5O&(U)ZG'?\3S5VBHE-RW-Z.'
MA2;<=V<YJOAQYIWGLRH+G+1MP,^H-9J^'M4<JK1*JC@%I00/IBNUHKQ*V0X2
MK4<]5?=)Z'6JLDK&=I.DIID3?-OF?[SXQ^`]JAU[3[C4((4MPA*/D[FQVK7H
MKNE@:+P_U9*T?(GF=^8S-#LI["Q:&<*',A;Y3GCBJWC#17\0^%-0TR+9YTL8
M,1<X`=2&7GMR!6Y16U"E&A3C3ALB9KG33ZGD7@?X;:UH_BNVU+54M5M[=791
M'+O)<C`XP/4G\*]=HHK>4G)W9E1HPHQY8'CFK?#CQ%>>-[C5H8[3[*]^)U)G
MPVP,#TQUP*];OK.+4+"XLYP3%/&T;X]",58HH<FPIT84[VZGA/\`PK+QCH^L
M[](9"$8B*\CN!&=I]0>1QU`!JUK/PH\0SFWFBNHKZ\E1FO)YYR,OG@+D$X`[
MU[915>UD8?4:5FM;'.VOAUI_`,?A[4"$=[+[/(T9W;6VXR#WP>:\HM_AQXXT
M?5#)IH1'&5%U!=*@*GU!YQ[8->\T4E-HTJ86%2U^AXGJOPG\1SI!=?;8K[4)
M<FZ>:8@+TVA21D]_3Z5Z9X)TF\T/PA8Z;?K&MS!O#"-]PY=F'/T(KH**3FVK
M,=/#0IR<H[A1114FYGZ]82ZIX?U&PA?RY;FVDB1LXPS*0.:\[L_%7Q$LHA8W
M7A=KNYC^3[1MP&]R0<'ZC%>J452=C*=-R=T['FO]B_$'Q/QJVJPZ+9-]Z"S_
M`-81Z%AS^M=+X:\"Z'X7/FV=N9;PCYKJ8[G]\?W?P_'-=+10Y,(T8I\SU?F%
M%%%2:A1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
..444`%%%%`!1110!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>v053088_ex99-2.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="50%">
            </td>
            <td width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><IMG SRC="psivida.jpg"></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td width="50%">
              <div><strong><font size="2">ASX RELEASE</font></strong></div>
            </td>
            <td width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><strong><font size="2">19
                September,
                2006</font></strong></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Results
      of General Meeting</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>held
      19</strong></font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><sup><strong>th</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>
      September, 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
      <div>&#160;</div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Boston,
      MA. and Perth, Australia - Global bio-nanotech company pSivida Limited (ASX:PSD,
      NASDAQ:PSDV, Xetra:PSI) held a General Meeting today at 3.00pm WST at Level
      2,
      QV1, 250 St George&#8217;s Terrace, Perth WA 6000.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All
      resolutions were passed unanimously by shareholders as follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Resolution
      1 - Ratification of Issue of Additional Warrants in respect of American
      Depositary Shares and ratification of amendments to the terms of the
      Notes</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 28.25pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 28.25pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>That,
      for the purposes of Listing Rule 7.4 of the Listing Rules of Australian Stock
      Exchange Limited, and for all other purposes, the Company
      ratifies:</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 28.25pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 63pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>(a)&#160;&#160;</em></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>the
              issue of Additional Warrants in respect of American Depositary Shares;
              and</em></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 28.25pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 63pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>(b)&#160;&#160;</em></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>the
              amendment to the terms of the Notes,</em></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 28.25pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 28.25pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>in
      each case on the terms and conditions set out in the Explanatory Memorandum
      accompanying this Notice.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 28.25pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Resolution
      2 - Approval of the Issue of US$6,500,000 in Subordinated Convertible New Notes
      and New Warrants in respect of 2,925,000 American Depositary
      Shares</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font id="TAB1" style="MARGIN-LEFT: 45pt"></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>That,
      for the purposes of Listing Rule 7.1 of the Listing Rules of Australian Stock
      Exchange Limited, and for all other purposes, the Company approves the issue
      of:</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 28.25pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 63pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>(a)&#160;&#160;</em></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>US$6,500,000
              in Subordinated Convertible New Notes;
              and</em></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 28.25pt" align="justify"><br></div>
    <table cellpadding="0" cellspacing="0" id="list" width="100%">

        <tr valign="top" style="line-height: 1.25;">
          <td align="right" style="width: 63pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>(b)&#160;&#160;</em></font></td>
          <td>
            <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>New
              Warrants in respect of 2,925,000 American Depositary
              Shares,</em></font></div>
          </td>
        </tr>

    </table>
    <div style="DISPLAY: block; MARGIN-LEFT: 63pt; TEXT-INDENT: -36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 28.25pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 28.25pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>in
      each case on the terms and conditions set out in the Explanatory Memorandum
      accompanying this Notice.</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Results
      of the Resolutions</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Each
      resolution was passed unanimously by a show of hands.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      results of the proxy votes received were as follows:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="justify" valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Resolution</strong></font></div>
            </td>
            <td valign="top" width="2%">&#160;</td>
            <td valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For</strong></font></div>
            </td>
            <td valign="top" width="12%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Against</strong></font></div>
            </td>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Abstain</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="justify" valign="top" width="3%">&#160;</td>
            <td align="justify" valign="top" width="37%">&#160;</td>
            <td align="right" valign="top" width="2%">&#160;</td>
            <td align="right" valign="top" width="13%">&#160;</td>
            <td align="right" valign="top" width="12%">&#160;</td>
            <td align="right" valign="top" width="10%">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="justify" valign="top" width="3%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1</font></div>
            </td>
            <td align="justify" valign="top" width="37%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ratification
                of Issue of Additional Warrants in respect of American Depositary
                Shares
                and ratification of amendments to the terms of the Notes</font></div>
            </td>
            <td align="right" valign="top" width="2%">&#160;</td>
            <td align="right" valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">112,380,463</font></div>
            </td>
            <td align="right" valign="top" width="12%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,003,614</font></div>
            </td>
            <td align="right" valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28,000</font></div>
            </td>
          </tr>
          <tr bgcolor="white">
            <td align="justify" valign="top" width="3%">&#160;</td>
            <td align="justify" valign="top" width="37%">&#160;</td>
            <td align="right" valign="top" width="2%">&#160;</td>
            <td align="right" valign="top" width="13%">&#160;</td>
            <td align="right" valign="top" width="12%">&#160;</td>
            <td align="right" valign="top" width="10%">&#160;</td>
          </tr>
          <tr bgcolor="#ccffcc">
            <td align="justify" valign="top" width="3%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
            </td>
            <td align="justify" valign="top" width="37%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approval
                of the Issue of US$6,500,000 in Subordinated Convertible New Notes
                and New
                Warrants in respect of 2,925,000 American Depositary
                Shares</font></div>
            </td>
            <td align="right" valign="top" width="2%">&#160;</td>
            <td align="right" valign="top" width="13%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">112,379,463</font></div>
            </td>
            <td align="right" valign="top" width="12%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1,004,614</font></div>
            </td>
            <td align="right" valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28,000</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Note
      that
      the proxy votes received represent 28.5% of voting shares on issue</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      announcement does not constitute an offer of any securities for sale or the
      solicitation of an offer to buy any securities. Any securities issued may not
      be
      or have not been registered under the US Securities Act of 1933, as amended,
      and
      may not be offered or sold in the United States absent registration or an
      applicable exemption from registration requirements.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="left" valign="top" width="34%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 943 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="left" valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>European
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accent
                Marketing Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Eva
                Reuter</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +49 (254) 393 0740</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">e.reuter@e-reuter-ir.com</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is a global bio-nanotech company committed to the biomedical sector and the
      development of drug delivery products. Retisert&#8482; is FDA approved for the
      treatment of uveitis. Vitrasert&#174; is FDA approved for the treatment of
      AIDS-related CMV Retinitis. Bausch &amp; Lomb own the trademarks Vitrasert&#174; and
      Retisert&#8482;. pSivida has licensed the technologies underlying both of these
      products to Bausch &amp; Lomb. The technology underlying Medidur&#8482;, a treatment
      for diabetic macular edema, is licensed to Alimera Sciences and is in Phase
      III
      clinical trials.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns the rights to develop and commercialise a modified form of silicon
      (porosified or nano-structured silicon) known as BioSilicon&#8482;, which has
      applications in drug delivery, wound healing, orthopaedics, and tissue
      engineering. pSivida&#8217;s subsidiary, AION Diagnostics Limited is developing
      diagnostic products and the subsidiary pSiNutria is developing food technology
      products both using BioSilicon&#8482;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
      intellectual property portfolio consists of 70 patent families, 74 granted
      patents and over 290 patent applications.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      pSivida
      conducts its operations from offices and facilities near Boston in the United
      States, Malvern in the United Kingdom, Perth in Australia and Singapore.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      and on
      the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
      Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company's largest shareholder and a strategic partner is QinetiQ, a leading
      international defence, security and Technology Company, formed in 2001 from
      the
      UK Government's Defence Evaluation &amp; Research Agency (DERA). QinetiQ (QQ.)
      was instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      pSivida&#8217;s strong relationship with QinetiQ includes access to its cutting edge
      research and development facilities.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties. The statements reference potential products, applications and
      regulatory approvals. Although we believe that the expectations reflected in
      such forward-looking statements are reasonable at this time, we can give no
      assurance that such expectations will prove to be correct. Given these
      uncertainties, readers are cautioned not to place undue reliance on such
      forward-looking statements. Actual results could differ materially from those
      anticipated in these forward-looking statements due to many important factors
      including: our inability to raise additional funds at favourable terms or any
      terms; our inability to repay the amended notes; issues relating to share
      registration in the U.S. that may delay our registration; our inability to
      develop proposed products, including without limitation, in the drug delivery,
      wound healing, orthopaedics, and tissue engineering, diagnostics and food
      technology fields; failure of our evaluation agreements to result in license
      agreements; failure to develop applications for BioSilicon&#8482; due to regulatory,
      scientific or other issues; failure to complete negotiations for new centers
      for
      the BrachySil&#8482; phase&#160;IIb clinical trial for inoperable primary liver
      cancer; failure of our discussions with the FDA for BrachySil&#8482; to continue or to
      lead to FDA approval; failure of the BrachySil&#8482; phase&#160;IIb clinical trial
      for inoperable primary liver cancer to determine the optimal dose, provide
      key
      safety data or support future pivotal efficacy trials or product registration
      or
      approval; failure of the BrachySil&#8482; primary liver programme that is in
      phase&#160;IIb clinical trials to&#160;provide a valuable platform for the
      development and commercialisation of BrachySil&#8482; for pancreatic cancer and other
      indications; failure to commence phase&#160;IIa BrachySilTM trials for the
      treatment of pancreatic cancer; failure of the findings&#160;of the pancreatic
      cancer phase&#160;IIa trial to provide a platform for further multicentre
      efficacy and safety trials; failure of there to be optimisation&#160;and
      standardisation between our two&#160; pancreatic cancer&#160;study&#160;centres;
      failure of the results of the Retisert&#8482; for DME trial to be a good indicator of
      the results of pSivida&#8217;s ongoing phase&#160;III Medidur&#8482; for DME trial; failure
      of the Medidur&#8482; trials in DME to show a very similar improvement in visual
      acuity and diabetic retinopathy severity score as Retisert&#8482; for DME; failure of
      Medidur&#8482; to release fluocinolone acetonide at the same rate as Retisert&#8482;; our
      inability to recruit patients for the phase&#160;III Medidur&#8482; for DME trial.
      Other reasons are contained in cautionary statements in the Annual Report on
      Form 20-F filed with the U.S. Securities and Exchange Commission, including,
      without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake
      to update any oral or written forward-looking statements that may be made by
      or
      on behalf of pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="1">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SUBMISSION>
